Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities

Tannock, Gerald W.; Tiong, Ing Soo; Priest, Patricia; Munro, Karen; Taylor, Corinda; Richardson, Alice; Schultz, Michael

doi:10.1099/jmm.0.025874-0

Cited by 45 publications

(34 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-pathogenic E . coli strains such as Nissle 1917 (EcN) are also classified as probiotics and have been studied in animals, normal volunteers, and elderly patients [60-64]. …”

Section: Are There Methods To Prevent or Treat Gut Colonisation With mentioning

confidence: 99%

The gut is the epicentre of antibiotic resistance

Carlet

2012

Antimicrob Resist Infect Control

175

141

View full text Add to dashboard Cite

The gut contains very large numbers of bacteria. Changes in the composition of the gut flora, due in particular to antibiotics, can happen silently, leading to the selection of highly resistant bacteria and Candida species. These resistant organisms may remain for months in the gut of the carrier without causing any symptoms or translocate through the gut epithelium, induce healthcare-associated infections, undergo cross-transmission to other individuals, and cause limited outbreaks. Techniques are available to prevent, detect, and treat the carriage of resistant organisms in the gut. However, evidence on these techniques is scant, the only exception being selective digestive decontamination (SDD), which has been extensively studied in neutropenic and ICU patients. After the destruction of resistant colonizing bacteria, which has been successfully obtained in several studies, the gut could be re-colonized with normal faecal flora or probiotics. Studies are warranted to evaluate this concept.

show abstract

“…Non-pathogenic E . coli strains such as Nissle 1917 (EcN) are also classified as probiotics and have been studied in animals, normal volunteers, and elderly patients [60-64]. …”

Section: Are There Methods To Prevent or Treat Gut Colonisation With mentioning

confidence: 99%

The gut is the epicentre of antibiotic resistance

Carlet

2012

Antimicrob Resist Infect Control

175

141

View full text Add to dashboard Cite

show abstract

“…The effect of a probiotic product containing different species (Bifidobacterium bifidum, B. lactis, Enterococcus faecium, Lactobacillus acidophilus L. paracasei, L. plantarum, L. rhamnosus, and L. salivarius) against ampicillin-resistant enterococcal intestinal colonization was studied in wards with a documented high prevalence of such bacteria, but the probiotics could not prevent colonization by the resistant enterococci (24). Other published assays concern resistant E. coli: a doubleblind, placebo-controlled trial was conducted to evaluate whether a probiotic product with E. coli strain Nissle 1917 (Mutaflor) could compete with the multidrug-resistant E. coli isolates in patients in long-term-care facilities, but after 5 weeks of treatment, the authors did not observe a significant difference in the carriage of multiresistant E. coli between the probiotic and placebo groups (25). These disappointing observations concerning the ability of probiotics to competitively exclude resistant bacteria are somewhat counterbalanced by the findings described in a paper by Nuotio et al (26).…”

Section: Discussionmentioning

confidence: 99%

Escherichia coli Probiotic Strain ED1a in Pigs Has a Limited Impact on the Gut Carriage of Extended-Spectrum-β-Lactamase-Producing E. coli

Mourand

Paboeuf

Fleury

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Four trials were conducted to evaluate the impact of Escherichia coli probiotic strain ED1a administration to pigs on the gut carriage or survival in manure of extended-spectrum-␤-lactamase-producing E. coli. Groups of pigs were orally inoculated with strain E. coli M63 carrying the bla CTX-M-1 gene (n ϭ 84) or used as a control (n ϭ 26). In the first two trials, 24 of 40 E. coli M63-inoculated pigs were given E. coli ED1a orally for 6 days starting 8 days after oral inoculation. In the third trial, 10 E. coli M63-inoculated pigs were given either E. coli ED1a or probiotic E. coli Nissle 1917 for 5 days. In the fourth trial, E. coli ED1a was given to a sow and its 12 piglets, and these 12 piglets plus 12 piglets that had not received E. coli ED1a were then inoculated with E. coli M63. Fecal shedding of cefotaxime-resistant Enterobacteriaceae (CTX-RE) was studied by culture, and bla CTX-M-1 genes were quantified by PCR. The persistence of CTX-RE in manure samples from inoculated pigs or manure samples inoculated in vitro with E. coli M63 with or without probiotics was studied. The results showed that E. coli M63 and ED1a were good gut colonizers. The reduction in the level of fecal excretion of CTX-RE in E. coli ED1a-treated pigs compared to that in nontreated pigs was usually less than 1 log 10 CFU and was mainly observed during the probiotic administration period. The results obtained with E. coli Nissle 1917 did not differ significantly from those obtained with E. coli ED1a. CTX-RE survival did not differ significantly in manure samples with or without probiotic treatment. In conclusion, under our experimental conditions, E. coli ED1a and E. coli Nissle 1917 could not durably prevent CTX-RE colonization of the pig gut.

show abstract

“…Although the initial results for carbapenemase carriers appeared promising (122), those obtained subsequently with ESBL-E carriers were disappointing, with short-lived ESBL-E elimination after the end of the procedure (123). Others have tried to use probiotics (124), but this was also a failure. Overall, it seems that far more research is warranted in the field before any practical solution can be proposed.…”

Section: How To Prevent and Reduce Esbl Carriage In Community Populatmentioning

confidence: 99%

Trends in Human Fecal Carriage of Extended-Spectrum β-Lactamases in the Community: Toward the Globalization of CTX-M

et al. 2013

View full text Add to dashboard Cite

SUMMARY In the last 10 years, extended-spectrum β-lactamase-producing enterobacteria (ESBL-E) have become one of the main challenges for antibiotic treatment of enterobacterial infections, largely because of the current CTX-M enzyme pandemic. However, most studies have focused on hospitalized patients, though today it appears that the community is strongly affected as well. We therefore decided to devote our investigation to trends in ESBL-E fecal carriage rates and comprehensively reviewed data from studies conducted on healthy populations in various parts of the world. We show that (i) community ESBL-E fecal carriage, which was unknown before the turn of the millennium, has since increased significantly everywhere, with developing countries being the most affected; (ii) intercontinental travel may have emphasized and globalized the issue; and (iii) CTX-M enzymes, especially CTX-M-15, are the dominant type of ESBL. Altogether, these results suggest that CTX-M carriage is evolving toward a global pandemic but is still insufficiently described. Only a better knowledge of its dynamics and biology will lead to further development of appropriate control measures.

show abstract

Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities

Cited by 45 publications

References 11 publications

The gut is the epicentre of antibiotic resistance

The gut is the epicentre of antibiotic resistance

Escherichia coli Probiotic Strain ED1a in Pigs Has a Limited Impact on the Gut Carriage of Extended-Spectrum-β-Lactamase-Producing E. coli

Trends in Human Fecal Carriage of Extended-Spectrum β-Lactamases in the Community: Toward the Globalization of CTX-M

Contact Info

Product

Resources

About